Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 1997

View Archived Issues

Known heart failure drug studied for AML

Neuropeptide Y: a new target in anxiety therapy

Clinical PK/PD study of TxA2 antagonist

Gastrointestinal role of GLP-1(7-36 amide) explored

Positive efficacy profile reported for Immunex's TNF receptor

Oxford BioMedica receives grant for the development of anticancer technology

Forbes Medi-Tech submits patent, reports on clinical trials

Generic clindamycin approved by FDA

Update on status of Cortex's Ampakine compound

Allos Therapeutics reports clinical results of RSR13

New ceftizoxime prodrug: bioavailability, pharmacokinetics and safety

Preclinical and clinical pharmacokinetic, safety and efficacy data reported for Synercid

Oncogene Science and Hoechst Marion Roussel extend collaboration

Update on SIBIA's candidate for Alzheimer's diseases

Genelabs and UCSF sign agreement for asthma clinical study

Targeted Genetics cancer gene therapy product approved for European clinical trials

Human Genome Sciences and SmithKline Beecham modify diagnostic agreement

FDA advisory committee recommends approval of rituximab

First launch for Duract

Tularik identifies protein kinase involved in inflammatory pathways

Calcium supplementation does not prevent life-threatening disorder of pregnancy

Hybridon suspends development of GEM-91 for AIDS

Abgenix and Neugenesis collaborate on monoclonal antibody production

Kosan receives NIAID grant for combinatorial biosynthesis of antifungal agents

BioTime's Hextend enters European clinical trials; licensed to Abbott

Potential alternative for long-term treatment of obesity

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...